Newamsterdam emerges with a cholesterol-lowering drug for statin-intolerant patients Aug. 25, 2020 By Nuala Moran No Comments LONDON – Five years after offloading it to Amgen Inc. for $300 million, Dutch VC Forbion has reacquired Dezima Pharma BV and its sole product obicetrapib, a cholesterol-lowering drug for patients intolerant to statins.Read More